Biotech Catalyst Trading Strategy: How FDA Events Move Stocks and What It Really Takes to Trade Them

Few corners of the market are as tempting as biotech catalyst trading. A small company has a single drug awaiting a regulatory decision, the stock is trading on little else, and the outcome will arrive on a known date. If the FDA approves, the shares can leap.

If it does not, they can collapse. The setup looks like a chance to be right about a clearly defined event and be paid handsomely for it.

The reality is more demanding. A catalyst is a known event, but the market knows about it too, which means most of the information is already in the price by the time a trader arrives.

What is left is a bet on whether the outcome is better or worse than what the price implies, usually with a loss on the downside that is much larger than the gain on the upside.

This article walks through how catalyst trading works, what the success-rate and price-reaction evidence says, the main ways traders approach it, and how to work out whether a particular setup is worth the risk.

What a Biotech Catalyst Actually Is

A catalyst is a scheduled or semi-scheduled event that can change the market’s view of a company’s value. In biotech the main ones are:

• Clinical trial readouts. The release of results from a Phase 1, 2 or 3 study, which show whether a drug appears to work and whether it is safe.
• Regulatory decisions. The FDA’s decision on a marketing application, tied to a target date known as the PDUFA date.
• Advisory committee meetings. Panels of outside experts that vote on a drug and give a signal, though not a binding one, about the likely decision.
• Medical conference presentations. Data shown at scientific meetings, sometimes for the first time and sometimes in more detail than an earlier press release.
• Corporate events. Partnerships, financings and acquisitions.

A PDUFA date is described as the target deadline set by the FDA for completing its review of a new drug or biologic application.

A standard review takes roughly ten months, while a priority review for drugs addressing unmet medical needs takes roughly six.

It is a target rather than a guarantee: decisions generally arrive on or around the date, but they can come earlier or slightly later, and the FDA can extend the timeline if a company submits major new information after filing.

Anyone trading around a PDUFA date should treat the date as an approximate window rather than an exact appointment.

What the Odds Look Like at Each Stage

The best-known industry dataset on drug development success is the BIO, Informa and QLS report on clinical development success rates for 2011 to 2020, which covers 12,728 phase transitions across 9,704 development programmes at 1,779 companies. Its headline figures show how unevenly risk is spread across a drug’s life.

Two points stand out. First, the filing-to-approval rate is high at around 90%, and the report notes that it includes resubmissions after rejection, so it reflects eventual success rather than first-time approval.

Second, the steepest drop is between Phase 2 and Phase 3, where fewer than three in ten drugs move forward. In other words, the biggest scientific risk is concentrated in mid-stage trials, while a drug that has already reached a regulatory decision has survived most of the filtering.

That is exactly why a high base rate for approval does not translate into an easy trade. Everyone can see that a filed drug is usually approved, and the share price tends to reflect it.

A 90% historical rate does not tell you whether the stock is priced for 80% odds or 95% odds, and that gap is the only thing a trader can actually profit from.

The Asymmetry Problem: Rejections Are Brutal

When the FDA does not approve an application it issues a complete response letter, or CRL, which states that the application cannot be approved in its current form.

The causes fall broadly into manufacturing and quality issues, gaps in the clinical data, and disagreements over labelling.

A CRL is not always the end: a minor fix can lead to a Class 1 resubmission with a review of around two months, while a substantial one takes a Class 2 resubmission of around six months.

The market reaction to a CRL can nonetheless be severe. RTTNews compiled recent examples of intraday declines from the prior close:

The spread in that table is the lesson. A large, diversified company like AbbVie barely moved on a single rejection because one drug is a small part of the business.

For a company whose value rests on one product, the same event can remove half or more of its market value within hours. Some of these stocks did recover.

The same report notes that Fortress Biotech rallied about 70% from its CRL low after an approval on a resubmission. But recovery depends on the cause of the rejection and the time and cash the company has left, and a trader who held through the event cannot count on it.

Does the Stock Run Up Before the Event?

The popular idea is that biotech stocks climb into a decision and then fall once the news is out, the classic “buy the rumour, sell the news” pattern.

There is a logical case for it: if a stock has risen sharply on anticipation, an approval that was already expected may not push it higher, and a company often raises money after approval, which can dilute existing shareholders.

One biotech education site makes exactly this argument, noting that an approval does not generate immediate revenue and that post-approval equity offerings can weigh on the stock.

The empirical picture is less tidy than the folklore. An independent data site, pdufa.bio, reports on its analysis of 1,752 clinical readouts that the median move was 3.8%, that 57% of readouts landed within plus or minus 5%, that 7.6% fell by 30% or more, and that it found no systematic run-up.

I have not been able to audit that site’s methodology, and it only describes its own sample, so these figures are best read as one data point rather than a settled fact.

Peer-reviewed event studies on FDA announcements exist, but I could not access them to check what they conclude, so I will not claim their findings here.

What the available evidence supports is narrower: typical moves around catalysts are often modest, a minority are extreme, and a reliable, repeatable run-up is not something you can assume.

Four Common Ways Traders Approach a Catalyst

None of these removes the central difficulty. Holding through the event is a pure binary bet. Trading the run-up depends on a pattern the data above does not support as reliable.

Waiting for confirmation avoids the binary risk but gives up the cheapest entry. Options cap the loss at the premium paid, but traders who use them are paying for volatility that the market has already priced in.

One widely cited guide to FDA trades notes that implied volatility can collapse after the event and erase gains even when the direction is right.

However, we could not find reliable data on how options on individual biotech names are priced against realised moves around specific catalysts, so any claim that options are systematically cheap or expensive going into events should be treated with caution.

A Worked Example: Why the Edge Depends on What Is Priced In

The same expectancy logic that applies to forex strategies applies directly here. Suppose, purely as a hypothetical, that you buy a stock the day before an FDA decision.

Assume the stock gains 15% on approval and loses 50% on a rejection, and that you estimate an 85% chance of approval.

Expected return per trade is (0.85 × 15%) − (0.15 × 50%) = 12.75% − 7.5% = +5.25%. That looks like a healthy edge. Now change one assumption: the stock was already heavily bid up, so approval only adds 8%.

The calculation becomes (0.85 × 8%) − (0.15 × 50%) = 6.8% − 7.5% = −0.7%. The same drug, the same approval odds and the same loss on rejection, but the trade has gone from attractive to negative purely because less upside was left.

The breakeven approval probability makes the point more directly. Using the formula Risk ÷ (Risk + Reward) from the risk-reward discussion elsewhere on this site, a 50% downside and a 15% upside require an approval probability of 50 ÷ 65, or about 77%, just to break even. With only an 8% upside, that rises to 50 ÷ 58, or about 86%.

The more the market has already paid for a good outcome, the more certain you need to be that it will happen, and the less margin you have for being wrong.

This is also why the high filing-to-approval rate in the table above is not a licence to buy every pending decision. Whether a trade has an edge depends on the distance between your estimate of the odds and the odds implied by the price, not on the base rate alone.

Position Sizing and Risk Control

Because the loss on a failed catalyst can be 50% or more of a position in a single session, and because a stop-loss order cannot protect you from a gap that opens far below it, position size is the main real control you have.

A commonly cited guideline in catalyst trading is to limit any single event position to a small share of the portfolio, often 1 to 3%, and to spread risk across several independent events rather than concentrating on one.

These are rules of thumb from trading guides rather than tested standards, but the arithmetic behind them is sound. A 2% position that loses half its value costs 1% of the portfolio, which is survivable.

A 20% position that loses half costs 10%, which is not a loss most traders recover from quickly.

Diversifying across catalysts matters for the same reason that win rate alone does not describe a strategy: a handful of trades says almost nothing about whether an approach has an edge.

If a trader takes five events and four of them happen to go the right way, that is not evidence of skill. If the sixth is a rejection at a 70% loss, it can erase the whole run.

Judging a catalyst approach properly takes a large number of independent events, a consistent method for estimating odds in advance, and a record that can be tested honestly, in the way described in the backtesting guide.

A Pre-Trade Checklist

1. Define the catalyst and its date range. Know exactly what event you are trading and treat PDUFA dates as windows, not exact times.
2. Estimate what is priced in. Compare your own view of the odds with what the share price and recent run-up imply. If you cannot say what the market expects, you have no way of knowing whether you have an edge.
3. Know the downside in advance. Look at how comparable rejections or failures have moved similar stocks, and size the position so that loss is acceptable.
4. Check how dependent the company is on the event. A single-product company reacts very differently from a diversified one, as the CRL table shows.
5. Look at cash and dilution risk. A company short of funds may raise capital immediately after good news, which can cap or reverse a gain.
6. Check liquidity and costs. Smaller biotech stocks can have wide spreads and thin trading, which raises the cost of getting in and out, particularly after a gap.
7. Decide your exit plan before the event. Decide in advance whether you will sell before the decision, hold through it, or take profits after a spike, rather than improvising when the price is moving.

Key Takeaways

Biotech catalyst trading is not a trade on whether a drug will be approved. It is a trade on whether the outcome will be better or worse than what the price already implies, with losses that are usually much larger than the gains.

The historical success rate for filed drugs is high, which is precisely why a good outcome is rarely a surprise.

Rejections can remove half or more of a single-product company’s value in a day, evidence for a dependable pre-event run-up is thin, and options bring their own cost in the form of volatility that falls away after the news.

The practical approach is to treat each event as one binary outcome, estimate what is priced in before entering, use the breakeven calculation to see how confident you actually need to be, keep position sizes small enough that a failure is survivable, and spread risk across many independent events rather than relying on any single one.

This article is for educational purposes and does not constitute financial advice. The worked example uses hypothetical figures. Trading biotech stocks and options involves a high level of risk, including the potential loss of the full amount invested, and may not be suitable for all investors.